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Purpose: The primary objective of these investigations was to determine the ocular biodistribution of bevasiranib, a small
interfering RNA (siRNA) targeting vascular endothelial growth factor A (VEGF-A), following a single intravitreal
injection to rabbit eyes.
Methods: A tissue distribution and pharmacokinetic study was conducted with 3H-bevasiranib prepared in balanced-salt
solution (BSS). Single doses of either 0.5 mg/eye or 2.0 mg/eye of 3H-bevasiranib were given by intravitreal injection to
Dutch-Belted rabbits (both eyes were treated). Subgroups of rabbits were serially-sacrificed at various times up to 7 days
following dosing for collection of tissue samples. The right eye of each rabbit was collected whole, and the left eye was
dissected to isolate five ocular tissues. All samples were analyzed by liquid scintillation counting to determine the
concentrations  of  bevasiranib  equivalents.  An  ocular  disposition  study  was  also  performed  with  non-radiolabeled
bevasiranib, which was administered to Dutch-Belted rabbit eyes via intravitreal injection at a dose of 2.0 mg/eye. Twenty-
four hours post-dose, the eyes were enucleated and dissected into eight individual ocular structures that were analyzed for
intact bevasiranib using a locked nuleic acid (LNA) noncompetitive hybridization-ligation enzyme-linked immunosorbent
assay.
Results: Following intravitreal injection of 0.5 mg or 2.0 mg radiolabeled bevasiranib to Dutch-Belted rabbits, bevasiranib
was detected in the vitreous, iris, retina, retinal pigment epithelium (RPE), and sclera (+choroid). As expected, the highest
concentrations were found in the vitreous, and vitreous levels steadily decreased over time, while concentrations of
radioactivity in the other ocular tissues increased to maximum values between 24 h and 72 h after dosing. Of these tissues,
the highest concentration of radioactivity was detected in the retina. The LNA assay further confirmed the presence of
intact bevasiranib in these tissues 24 h following intravitreal injection of non-radiolabeled bevasiranib (2 mg/eye).
Conclusions: These studies demonstrate distribution of bevasiranib throughout the eye following intravitreal injection,
including extensive uptake into the retina.
Age-related macular degeneration (AMD) is the leading
cause of severe vision loss in the elderly [1,2]. Although the
etiology of the disease is still not completely elucidated, it is
clear that vascular endothelial growth factor (VEGF) plays a
major role in the disease process. VEGF is a key mediator of
pathological and physiologic angiogenesis and is increased in
neovascular  membranes  of  patients  with  AMD  [3-6].
Pegaptanib, an RNA aptamer directed against VEGF-A, and
ranibizumab,  a  monoclonal  antibody  fragment  that  binds
VEGF-A, have both been approved by the United States Food
and Drug Administration for the treatment of neovascular
AMD [7,8].
RNA  interference  (RNAi)  is  a  ubiquitous  and
endogenous gene silencing mechanism found in eukaryotic
cells [9]. Its catalytic nature allows for one small interfering
RNA (siRNA) to guide the cleavage of thousands of mRNAs,
resulting in effective gene silencing [9]. Studies in mouse
models  of  retinal  and  choroidal  neovascularization  have
demonstrated the potential utility of this technology for the
treatment of ocular disorders, and clinical trials are currently
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underway  to  test  the  ability  of  small  interfering  RNAs
(siRNAs)  targeting  VEGF-A  (bevasiranib)  or  VEGFR1
(AGN211745/SIRNA-027) to treat wet AMD [10,11]. Both
siRNAs  are  being  delivered  to  the  eye  via  intravitreal
injections.
This paper describes results from a study designed to
assess the biodistribution of bevasiranib after an intravitreal
injection  in  rabbits.  To  accomplish  this,  bevasiranib  was
radiolabeled with tritium (3H) and injected intravitreally into
rabbit eyes once. Biodistribution and kinetics of radiolabeled
bevasiranib post-injection were studied over a 7 day period.
In addition, a bevasiranib-specific locked nucleic acid (LNA)
assay was developed and validated. It was used to confirm the
presence of intact bevasiranib in ocular tissue following a
single intravitreal injection of the non-radiolabelled siRNA to
rabbit  eyes.  Together  these  studies  demonstrate  the
distribution  of  bevasiranib  in  the  vitreous,  retina,  retinal
pigment epithelium (RPE), sclera, and choroid of rabbits after
a single intravitreal injection.
METHODS
All animal studies were performed in accordance with the
ARVO Statement for the Use of Animals in Ophthalmic and
Visual Research.
Molecular Vision 2008; 14:997-1005 <http://www.molvis.org/molvis/v14/a119>
Received 7 March 2008 | Accepted 22 April 2008 | Published 28 May 2008
© 2008 Molecular Vision
997siRNA: The sense strand sequence of bevasiranib is 5’-
ACC  UCA  CCA  AGG  CCA  GCA  CdTdT-3’,  while  the
antisense strand sequence is 5’-G UGC UGG CCU UGG
UGA  GGUdTdT-3’.  3H-Bevasiranib  was  synthesized  by
TriLink Bio Technologies, Inc. (San Diego, CA). On the day
of  dosing,  the  lyophilized  powder  was  dissolved  in  the
required volume of sterile balanced salt solution (BSS), pH
6.8–8.0, osmolality 334 mOsmol/l (Baxter Healthcare Corp,
Deerfield, IL), with stirring. The test article formulation was
prepared at a nominal concentration of 10 mg/ml (200 μCi/
ml) or 40 mg/ml (160 μCi/ml). A correction factor of 1.11 was
applied in dispensing the 3H-bevasiranib to adjust for purity.
Both  solutions  were  filtered  through  a  0.2  μm  Gelman
Acrodisc filter (Pall Life Sciences, Ann Arbor, MI) into sterile
vials. The specific activity was 20 µCi/mg (for the low dose)
and 4 µCi/mg (for the high dose).
Non-radiolabeled bevasiranib used for rabbit studies was
obtained from Transgenomic (Omaha, NE). Bevasiranib was
dissolved in 5% dextrose in water (D5W) forming a 40 mg/
ml solution. The solution was filtered through a PALL Life
Sciences Acrodisc® 13 mm syringe filter with a 0.2 μm HT
Tuffryn® Membrane (Pall Life Sciences). For intravitreal
injection, filtered material was loaded into 1 ml tuberculin
syringes fitted with 30 gauge needles and stored at 4 °C until
it was administered.
In vivo 3H-bevasiranib studies: A total of 16 male and 16
female  Dutch-Belted  rabbits  were  used.  At  the  onset  of
treatment, the animals were approximately 5 months in age,
and their body weights ranged from 1.9 to 2.9 kg.
Animals were randomized into 2 study groups: Group 1,
0.5 mg 3H-bevasiranib/eye; Group 2, 2.0 mg 3H-bevasiranib /
eye.  Immediately  before  anesthesia,  mydriatic  drops  (1%
Mydriacyl) were applied to the eyes. Prior to dosing, the
animals  received  an  intramuscular  sedative  injection  of  a
ketamine and xylazine cocktail. The conjunctivas were then
flushed with a 1:10,000 solution (equivalent to 0.1 mg/ml) of
benzalkonium  chloride  50%  NF  (Spectrum  Lab  Products,
Inc., New Brunswick, NJ) prepared in 0.9% (w/v) sodium
chloride  for  injection  USP  (Baxter).  A  local  anesthetic
(Alcain, 0.5%) was applied to each eye. For each injection, a
new insulin syringe (with pre-fitted needle) was used. Dose
formulation was administered by intravitreal injection in both
eyes at a dose volume of 50 µl/eye, using a binocular indirect
ophthalmoscope  to  confirm  needle  placement.  The
ophthalmologist examined the eyes immediately following
treatment  (indirect  ophthalmoscopy  and  slit-lamp
biomicroscopy) and documented any abnormalities caused by
the dosing procedure. Following examination, gentamycin
ophthalmic drops were applied to each eye and an ocular
lubricant (Tears Naturale®, Alcon, Fort Worth, TX) was used
if considered appropriate by the ophthalmologist.
Animals were euthanized at predetermined times (6, 24,
72,  and  168  h  post-injection)  by  intravenous  injection  of
Euthanyl® (Bimeda-MTC Animal Health Inc., Cambridge,
Ontario,  Canada;  approximately  200  mg/kg).  Two  female
animals and two male animals were sacrificed at each time
point. Following euthanasia, tissue was collected. The right
eye was removed intact. The left eye was dissected to collect
aqueous fluid, iris, vitreous fluid, retina and sclera (including
choroid). All samples were stored at -80 °C.
Radioactivity measurements: The total weights of the
tissue  samples  were  recorded.  Tissue  samples  were
solubilized in 35% tetraethylammonium hydroxide (TEAH).
The solubilized samples, or duplicate aliquots thereof, were
then mixed with liquid scintillation fluid before radioactivity
measurements.
Radioactivity measurements were conducted by liquid
scintillation spectroscopy. Each sample was counted for 5 min
or to a two-sigma error of 0.1%, whichever occurred first. All
counts  were  converted  to  absolute  radioactivity  (dpm)  by
automatic quench correction based on the shift of the spectrum
for the external standard. Samples that exhibited radioactivity
less  than  or  equal  to  twice  the  background  values  were
considered as zero for all subsequent manipulations.
All  radioactivity  measurements  were  entered  into  a
standard computer database program (Debra Version 5.2) for
the calculation of concentrations of radioactivity (dpm/g and
mass eq/g) and percentage of administered radioactivity in
each  sample.  Tissue  concentrations  of  radioactivity  were
calculated initially in dpm/g, and then mass eq/g (assuming
intact siRNA) was calculated on the basis of the measured
specific  activity  (dpm/mg  or  appropriate  mass  unit)  of
radiolabeled  test  article  in  the  dose  solution.  Total  tissue
content was calculated based on the total tissue weight.
Non-compartmental  pharmacokinetic  parameters  were
estimated for the ocular tissue data, using SAS Version 8.1,
and included area under the concentration versus time curve
(AUC), terminal half-life (t1/2el), terminal rate constant (kel),
the highest concentration observed (Cmax), and time at which
the highest concentration occurred (tmax). The Cmax was
obtained by data inspection. The AUC was calculated by
application of the trapezoidal rule and kel was obtained by
linear  regression  analysis  of  selected  time  points  in  the
terminal phase of the concentration versus time curves [12].
The  apparent  terminal  half-life  (t1/2el)  was  calculated  as
follows: t1/2el=ln2/kel. For all time deviations greater than
10%, the actual time collection was used for estimation of the
parameters.
In  vivo  non-radiolabeled  bevasiranib  studies:  Male
Dutch-Belted rabbits, ranging in weight from 2.0 to 2.4 kg,
were  used.  Animals  were  anesthetized  with  a  ketamine/
xylazine (8 ml ketamine: 1 ml xylazine) cocktail at 0.5 ml/kg
on Day 1. Eyes were then dilated with 2–3 drops of 1%
Tropicacyl® (tropicamide; Alcon) followed by 2-3 drops of
0.5%  proparacaine  as  an  analgesic.  Two  rabbits  received
bilateral intravitreal injections of 5% dextrose for injection
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998(D5W).  An  additional  three  rabbits  received  intravitreal
injections of bevasiranib prepared in D5W (Note: 5 of 6 eyes
were treated.). All injections were 50 μl in volume and made
with 1 ml syringes fitted with 30 gauge needles. Rabbits dosed
with bevasiranib received 2 mg/eye. The following day (24 h
post-dosing),  animals  were  euthanized.  Both  eyes  were
collected from each animal, and the eyes were dissected to
obtain  8  tissues/eye.  Tissues  were  frozen  on  dry  ice  and
ethanol  and  subsequently  stored  at  -80  °C  until  further
processing.
Homogenates were prepared from each tissue sample.
Briefly, sterile phosphate-buffered saline (PBS) was added to
each sample (500 μl-2 ml), and tissue was sonicated with a
Branson  Sonifier  150D  (Branson,  Danbury,  CT)  until  the
tissue was completely disrupted.
Following tissue disruption, samples underwent a series
of 3 freeze/thaw cycles to further lyse the cell membranes.
Each cycle consisted of freezing the samples in a dry ice/
ethanol bath, thawing the samples in a 37 °C water bath and
vortexing  the  samples.  Samples  were  subsequently
centrifuged  in  a  microfuge  at  ~18,000x  g  for  10  min.
Supernatants were transferred to fresh tubes, and all samples
were stored at -80 °C. Protein concentrations were determined
on the supernatant samples using the BCATM Protein Assay
Kit (Pierce Chemical, Rockford, IL), and the samples were
subsequently used for LNA analysis.
Reagents and chemicals for locked nuleic acid analysis:
A template probe, template probe working solution, wash
buffer, ligation probe, ligation probe working solution, anti-
digoxigenin-AP  working  solution,  and  detection  solution
were prepared. The template probe was 5’-GAA TAG CGA
A+A  AC+  CTC  +AC  C+A  AG+  GCC  +AG  C+A  C-
(BIOTIN)-3’  (capital  letters=DNA;  +=LNA;  (BIOTIN)=
biotin-TEG; Sigma, St. Louis, MO). It was rehydrated in 1X
PBS to a final concentration of 10 μM. The template probe
working  solution  was  prepared  by  combining  150  μl  of
10  μM  template  probe  with  30  ml  of  6X  SSPE/0.24%
Tween-20 to obtain a final concentration of 50 nM template
probe. The wash buffer was 1X Tris-buffered saline (TBS),
0.1% Tween-20. The ligation probe was 5’-(PHOSPHATE)-
TCG CTA TTC-(DIGOXIGENIN)-3’ (Invitrogen, Carlsbad,
CA). The probe was rehydrated in 1X One-Phor-All Buffer
PLUS  (10X  One-Phor-All  Buffer  Plus;  Amersham
Biosciences  Corporation,  Piscataway,  NJ)  to  a  final
concentration of 10 μM. The ligation probe working solution
was prepared by combining 10X One-Phor-All Buffer Plus
with T4 DNA ligase, ATP, water and 10 μM ligation probe.
The final concentration of the solution was 75 nM ligation
probe, 2 units/ml T4 DNA ligase, 0.10 mM ATP, 1X One-
Phor-All  Buffer  Plus.  The  Anti-digoxigenin-AP  working
solution  was  prepared  by  combining  11  μl  of  anti-
digoxigenin-AP,  Fab  fragments  (Roche  Applied  Sciences,
Indianapolis, IN) with 22 ml of Super-Block buffer working
solution. Super-Block buffer working solution was prepared
by adding 10 ml of SuperBlock® Blocking Buffer in TBS
(Pierce Chemical) to 90 ml of ultra pure water. Detection
solution was prepared by combining two, 5 mg PNPP (p-
nitrophenyl  phosphate  disodium  salt)  tablets  (Pierce
Chemical) with 8 ml water and 2 ml of 5X diethanolamine
substrate buffer concentrate (Pierce Chemical).
Locked nucleic acid enzyme-linked immunosorbent assay
protocol:  The  protocol  was  adopted  from  a  previously
described  method  and  optimized  for  bevasiranib  [13].
Bevasiranib standard siRNA and protein samples (0.5–40 μg)
were aliquoted into 1.5 ml Eppendorf tubes. The final volume
was adjusted to 150 μl with PBS. PBS served as a negative
control. 300 μl of template probe working solution was added
to each tube, and the contents were vortexed. Samples were
incubated at 90 °C for 10 min, cooled at room temperature for
15 min, placed in an ice water bath for 5 min and refrigerated
at  4  °C  for  1  h.  Tubes  were  subsequently  centrifuged  at
16,000x  g  for  15  min  at  4  °C.  Supernatant  (200  μl/well;
duplicate  wells)  was  then  transferred  to  Reacti-BindTM
NeutrAvidinTM Coated High Binding Capacity (HBC) Clear
96 well plates (Pierce Chemical). The plate was covered with
an adhesive strip and placed in a 37 °C incubator for 30 min.
The plate was then refrigerated at 4 °C for 10 min and washed
4 times with wash buffer. Care was taken after the final wash
to remove all traces of wash buffer. Similar care was taken for
all subsequent washes that followed.
Ligation  probe  working  solution  (200  μl)  was
subsequently added to each well. The plate was covered with
an adhesive strip and incubated at room temperature on an
orbital shaker (100 rpm) for 1 h. The plate was then washed
twice with wash buffer, 3 times with ultra pure water (wells
were soaked for 3 min during each water wash), and then one
last time with wash buffer.
Anti-digoxigenin-AP  working  solution  (200  μl)  was
added to each well. The plate was covered with an adhesive
strip and incubated on an orbital shaker (100 rpm) for 30 min
at room temperature. The plate was then washed 5 times with
wash buffer.
Then 100 μl of detection solution was added to each well.
The plate was covered with aluminum foil to maintain dark
conditions and was incubated at room temperature for 30 min.
NaOH (2 N; 50 μl) was added to each well. The optical density
of each well was determined at 405 nm using a microplate
reader.
Locked nucleic acid enzyme-linked immunosorbent assay
validation studies: Prior to tissue analysis, several validation
procedures  were  completed.  Linearity  of  dilution  of
bevasiranib in PBS was determined in the absence of protein
and intra-assay precision and accuracy were determined. The
lower limit of quantification (LLOQ) was 6.25 ng/ml, and the
upper limit of quantification (ULOQ) was 200 ng/ml. Finally,
selectivity of bevasiranib was determined in the presence of
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999protein. Rabbit eye homogenates, devoid of bevasiranib, were
used  for  these  assays.  Increasing  concentrations  of  rabbit
ocular  tissue  protein  (0–75  μg/ml)  had  no  effect  on
bevasiranib levels (Data not shown).
RESULTS
Ocular  responses  to  3H-bevasiranib  following  a  single
intravitreal injection: No systemic treatment-related clinical
signs  were  observed  in  the  rabbits  following  a  single
intravitreal dose of 3H-bevasiranib.
Ophthalmological evaluations were performed pre-dose,
directly after administration and at approximately 48 h and
144 h post-dose. For Group 1 (0.5 mg 3H-bevasiranib/eye) at
48 h, the most frequent observation was slight conjunctival
hyperemia (5/16 eyes). In addition, small numbers of vitreous
cells were observed in a single eye. By 144 h, no treatment
related  signs  were  observed  in  the  eyes  of  the  remaining
animals in Group 1.
At 48 h after dosing, the most frequent observation for
Group 2 animals (2.0 mg 3H-bevasiranib/eye) was congestion
of the retinal vessels (11/16 eyes) followed by mild anterior
uveitis  (7/16  yes)  and  slight  to  moderate  conjunctival
hyperemia (7/16 eyes). The most severely affected animal also
exhibited  bilateral  focal  retinal  hemorrhages.  By  144  h,
congestion of the retinal vessels was no longer present, but
variable numbers of vitreous cells were observed in all of the
eyes of the surviving animals. Focal opacity of the vitreous
(6/8 eyes), slight aqueous flare (4/8 eyes) and focal vitreous
hemorrhage (2/8 eyes) were also observed. In the absence of
a placebo group, it is difficult to assign causality of the above
mentioned,  transient  adverse  events.  Such  events  are
commonly  associated  with  injection  procedures  and
manipulation of the ocular surface.
3H-bevasiranib  localizes  to  the  retina  following  a  single
intravitreal  injection:  Radioactivity  derived  from  the  3H-
bevasiranib was detected in all the ocular structures examined,
and the values for percentage of the dose found in the tissues
were calculated using the doses administered to the individual
eye.
For males in Group 1, the highest mean concentration of
radioactivity in the ocular tissues/fluids was 429 μg-eq/g,
observed in the vitreous fluid of the left eye at 6 h after dosing
(the  first  time  point  measured;  Table  1).  Thereafter
concentrations in vitreous fluid decreased steadily over time
to 118 μg-eq/g by 72 h post-injection and to 10.4 μg eq/g by
168  h  post-dose  (2.4%  of  the  maximum  value).  Mean
concentrations of radioactivity in the other ocular tissues from
the left eye (retina, iris, sclera/choroid and aqueous fluid)
increased from 6 h to maximum values at 24 or 72 h after
dosing.  Of  these  tissues,  the  highest  concentration  of
radioactivity was observed in the retina at 72 h post-dose
(mean 370 μg-eq/g), and the level of radioactivity in the retina
did not diminish substantially between 72 and 168 h post-
dose.  Uptake  into  the  aqueous  fluid  of  the  left  eye  was
relatively low, with a mean concentration of 20 μg-eq/g at 24
h post-injection, diminishing to approximately 1 μg-eq/g by
168 h. Mean radioactivity concentrations for the whole right
eye showed a similar pattern to that of vitreous fluid, with the
mean Cmax at 6 h post-dose (205 μg-eq/g), decreasing to
18.3 μg-eq/g by 168 h.
Table 2 presents the mean percentage of the administered
dose found in each ocular structure. For males from Group 1,
at 6 h after dosing, a mean of 92.1% of the administered dose
remained in the right eye. At this time, the majority of the
radiolabeled material (mean 83.1%) was found in the vitreous
fluid (left eye data) with a further 5.5% found in the other
tissues of the left eye. Mean amounts of radioactivity in whole
eye, vitreous fluid and aqueous fluid generally decreased at
later time points, while those in iris, retina and sclera generally
increased, at least for the earlier time points. Similar trends
were also observed in female animals receiving the 0.5 mg/
eye treatment.
When 2.0 mg 3H-bevasiranib was administered to rabbits
(Group 2), males showed the highest mean concentration of
radioactivity in the vitreous fluid of the left eye at 6 h post-
dose (1,919 μg-eq/g; Table 1). Thereafter, concentrations in
vitreous decreased to 201 μg-eq/g at 168 h post-dose (10.5%
of the Cmax value). Mean concentrations of radioactivity in
sclera were also maximal at 6 h (341 μg-eq/g), whereas those
of the other ocular tissues from the left eye (retina, iris, and
aqueous fluid) increased to maximum values at 24 (aqueous
fluid), 72 (iris), or 168 h after dosing (retina). Of these tissues,
the highest concentration of radioactivity was observed in the
retina  (mean  683  μg-eq/g);  there  was  little  change  in  the
radioactivity level of the retina of Group 2 animals between
72 and 168 h post-dose. The mean radioactivity concentration
for the intact right eye exhibited a similar pattern to that of
vitreous, with the mean Cmax at 6 h post-dose (781 μg-eq/g),
decreasing to 149 μg-eq/g by 168 h.
At 6 h after dosing, a mean of 91.9% of the administered
dose  remained  in  the  right  eye,  with  the  majority  of  the
radiolabeled material (mean 65.1%) found in the vitreous (left
eye data) and 8.8% found in the other left eye tissues (Table
2). Mean amounts of radioactivity in whole eye, vitreous fluid
and sclera decreased at later time points, while those in iris,
retina and aqueous fluid generally increased, at least for the
earlier time points. Once again, female rabbits showed similar
results to that of the male counterparts in Group 2.
Pharmacokinetics  of  radioactivity  in  the  eye:  Mean
radioactivity  concentration  versus  time  data  were  used  to
calculate  pharmacokinetic  parameters  for  ocular  tissue.
AUC(0-t) values were calculated, where t corresponded to 168
h  post-dose  (the  last  time  point  taken).  Female  and  male
rabbits showed similar results (Table 3).
For male rabbits in Group 1, AUC(0–168h) values for
retina, vitreous, whole right eye, sclera, iris and aqueous fluid
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1000were 47,235 μg-eq·h/g, 24,725 μg-eq·h/g, 11,936 μg-eq·h/g,
8,916  μg-eq·h/g,  5,814  μg-eq·h/g,  and  1,654  μg-eq·h/g,
respectively.
For whole right eye and vitreous, sufficient data were
available  to  permit  estimation  of  kel,  the  half-life  of
elimination, t1/2 and the AUC(0-inf). For the right eye, kel
was 0.0124 h-1, t1/2 was estimated as 55.7 h, and the AUC
(0-inf) was 13,402 μg-eq·h/g (% extrapolation (t-inf) 10.9%),
whereas  for  vitreous  fluid  from  the  left  eye,  the  same
parameters  were  calculated  as  0.02  h-1,  30.0  h  and
25,176 μg-eq·h/g (% extrapolation [t-inf] 1.8%).
In contrast to the 0.5 mg/eye dose, male rabbits receiving
2.0 mg/eye (Group 2) achieved the highest AUC (0–168 h)
value  in  the  vitreous  fluid  (139,913  μg-eq·h/g).  This  was
followed  by  retina  (98,185  μg-eq·h/g),  whole  right  eye
(71,089  μg-eq·h/g),  sclera  (34,724  μg-eq·h/g),  iris
(25,065 μg-eq·h/g), and aqueous fluid (12,589 μg-eq·h/g).
For the right eye, kel, was 0.01 h-1, t1/2 was estimated as
69.0  h,  and  the  AUC(0-inf)  was  85,914  μg-eq·h/g
(extrapolation [t-inf] 17.3%). For vitreous fluid from the left
eye, the same parameters were calculated as 0.01 h-1, 51.7 h
and 154,893 μg-eq·h/g (extrapolation [t-inf] 9.7%).
Biodistribution of intact bevasiranib 24 h after intravitreal
injection: The data in Table 4 are representative of a single
experiment using 5 rabbits. The study was repeated on 3
additional occasions with similar results.
As anticipated, LNA analysis confirmed bevasiranib was
not  detected  in  any  ocular  tissue  following  intravitreal
injection of the D5W vehicle. Twenty-four hours following
TABLE 1. MEAN CONCENTRATION OF RADIOACTIVITY IN OCULAR TISSUES OF DUTCH-BELTED RABBITS FOLLOWING A
SINGLE INTRAVITREAL BOLUS INJECTION OF 
3H-BEVASIRANIB.
Concentration of radioactivity, μg eq/g
a
Group Sex Sample 6 h 24 h 72 h 168 h
1 Males Aqueous fluid 12.3 20.1 11 1.1
1 Males Eye (right) 205 105.1 71.3 18.3
1 Males Iris 12.8 31.7 50 21
1 Males Retina 103.7 221.5 370.2 250.6
1 Males Sclera (+ choroid) 65.4 88.7 54.3 27
1 Males Vitreous fluid 429.3 273.9 118.6 10.4
1 Females Aqueous fluid 3.9 28.9 10.5 1.2
1 Females Eye (right) 175 162 59.4 21.1
1 Females Iris 6.4 37.3 36.4 28.2
1 Females Retina 91 193.8 342.8 278.3
1 Females Sclera (+ choroid) 57 75.6 54.6 24.4
1 Females Vitreous fluid 355.2 307.6 113.7 12.2
2 Males Aqueous fluid 79.8 125.1 90.8 20.2
2 Males Eye (right) 781.2 599.8 483 148.9
2 Males Iris 79.3 134.9 188.6 126.7
2 Males Retina 380.2 416 654.5 682.7
2 Males Sclera (+ choroid) 340.6 329 207.7 100.6
2 Males Vitreous fluid 1919.3 1357.1 777.8 200.7
2 Females Aqueous fluid 119.9 126.9 52.1 19.9
2 Females Eye (right) 818.2 553.9 438.6 159.3
2 Females Iris 139.3 149 92.1 118.7
2 Females Retina 436.1 439.9 449 628.1
2 Females Sclera (+ choroid) 381.1 363 124.7 85.7
2 Females Vitreous fluid 1748.3 1362.6 504.4 205.9
Eight male and eight female rabbits (total 16 rabbits) were used for each treatment group. Group 1 animals received 0.5 mg
3H-bevasiranib/eye via intravitreal injection. Group 2 animals received 2.0 mg/bevasiranib/eye. Two animals of each sex (total
4 rabbits) were sacrificed at predetermined time points (6, 24, 72, and 168 h). Whole eyes (right eyes) and dissected ocular
tissues from left eyes were analyzed for levels of radioactivity. aMean, n=2
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1001intravitreal  injection  of  2  mg  bevasiranib/eye,  intact
bevasiranib was not detected in lens (4/5 eyes). Bevasiranib
was detected in aqueous fluid, vitreous fluid, iris, ciliary body,
RPE, choroid and retina, with the highest level in the vitreous
fluid, where the concentrations in 4/5 eyes were above the
ULOQ.
DISCUSSION
The  studies  described  herein  have  characterized  the
biodistribution of bevasiranib following a single intravitreal
injection in Dutch-Belted rabbits. Bevasiranib is a double-
stranded RNA oligonucleotide of 21 nucleotides in length
having one strand with a primary sequence that has Watson–
Crick homology to 21 nucleotides in the VEGF-A mRNA.
Reich  and  colleagues  previously  demonstrated  that
bevasiranib  decreased  levels  of  hVEGF  (imparted  via  an
adenovirus vector) in mouse RPE cells in vivo following
subretinal  injection  of  bevasiranib  [10].  The  effect  was
specific,  as  an  siRNA  targeting  EGFP  had  no  effect.  In
addition, they demonstrated that an siRNA targeting murine
VEGF  was  able  to  inhibit  choroidal  neovascularization
(CNV) in a laser-induced model of CNV, while, a control
siRNA targeting EGFP had no effect.
As  a  follow-up,  we  sought  to  determine  the
biodistriubtion of bevasiranib following intravitreal injection.
The intravitreal route of administration was considered the
likely route of delivery in treating VEGF-A mediated ocular
diseases  in  man,  such  as  neovascular-AMD  and  diabetic
retinopathy. At 6 h post-dose (the first time point), the highest
concentration of radioactivity in the tissues of all animals was
TABLE 2. MEAN RADIOACTIVITY CONTENT IN TISSUE OF DUTCH-BELTED RABBITS FOLLOWING A SINGLE INTRAVITREAL
BOLUS OF 
3H-BEVASIRANIB.
Percent of dose
a
Group Sex Sample 6 h 24 h 72 h 168 h
1 Males Aqueous fluid 0.5 0.4 0.5 0.05
1 Males Eye (right) 92.1 46.5 36.9 8.8
1 Males Iris 0.1 0.2 0.3 0.1
1 Males Retina 0.5 0.9 2 2.3
1 Males Sclera (+ choroid) 4.4 6 3.8 1.7
1 Males Vitreous fluid 83.1 41.2 20 1.7
1 Females Aqueous fluid 0.2 1.4 0.5 0.1
1 Females Eye (right) 85.7 76.1 29.6 10
1 Females Iris 0.04 0.2 0.2 0.2
1 Females Retina 0.5 1.2 2.3 2.8
1 Females Sclera (+ choroid) 4.5 4.8 4 1.3
1 Females Vitreous fluid 82.6 57.1 18.6 2
2 Males Aqueous fluid 0.9 1.2 0.9 0.2
2 Males Eye (right) 91.9 73.2 51.7 15.8
2 Males Iris 0.1 0.2 0.3 0.2
2 Males Retina 0.3 0.8 0.9 1.4
2 Males Sclera (+ choroid) 7.5 6.4 3.4 1.3
2 Males Vitreous fluid 65.1 54 37.5 8.1
2 Females Aqueous fluid 1.2 1.1 0.4 0.2
2 Females Eye (right) 90.5 60.1 47.7 17.5
2 Females Iris 0.2 0.2 0.1 0.2
2 Females Retina 0.5 0.7 0.9 1.5
2 Females Sclera (+ choroid) 6.6 5.4 1.7 1.1
2 Females Vitreous fluid 63.2 50.1 25.1 10.3
Male (n=8) and female (n=8) rabbits were treated with 3H-bevasiranib via intravitreal injection. Group 1 animals received 0.5
mg bevasiranib/eye. Group 2 animals received 2.0 mg/bevasiranib/eye. Two animals of each sex (total 4 rabbits) were sacrificed
at predetermined times (6, 24, 72, and 168 h) post-injection. Whole eyes (right eyes) and dissected ocular tissues from left eyes
were analyzed for levels of radioactivity. The mean percentage of radioactivity found in each ocular structure is reported. aMean,
n=2.
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1002found in the vitreous of the eye (i.e., the site of administration).
Concentrations  were  also  appreciable  in  the  other  ocular
tissues investigated (aqueous fluid, iris, retina, and sclera). For
these  ocular  tissues,  the  radioactivity  generally  (but  not
always)  increased  with  time  after  dosing,  indicating  the
migration of bevasiranib from the vitreous compartment into
various tissues of the eye. Among the ocular tissues examined,
the highest concentrations were present in the retina. The slow
increase  in  radioactivity  in  the  retina  indicated  that  this
radiolabeled material was transferred into and retained in the
retina and was not the product of cross-contamination from
the vitreous fluid. Radioactivity levels in retina generally did
not decline substantially between Cmax and the last time point
measured,  indicating  persistence  of  3H-bevasiranib-related
material  in  this  target  tissue  for  an  extended  period.  The
pattern of ocular distribution derived from 3H-bevasiranib was
similar for both male and female rabbits at both dose levels.
Pharmacokinetic  analyses  of  the  radioactivity
concentration versus time profiles for animals in Group 1
(0.5 mg/eye) indicated that the AUC (0–168 h) value for retina
was greater than that of vitreous fluid, therefore supporting
the interpretation that radiolabeled material had moved from
the vitreous fluid and accumulated in the retina. For the Group
2 animals (2 mg/eye), this relationship was reversed although
the mean AUC values for retina were again relatively high.
This may reflect partial saturation of the rate of uptake of
bevasiranib  into  the  retina  at  the  higher  dose  level.  The
pharmacokinetic parameters estimated for animals of both
sexes in each dose group were similar, again indicating that
there were no sex-related differences in the exposure of the
animals to 3H-bevasiranib and/or its metabolites. The half-life
of radioactivity in the vitreous fluid of both male and female
rabbits  following  administration  of  the  0.5  mg/eye  dose
exceeded 24 h. In the animals that received the 2.0 mg/eye
dose,  the  half-life  of  radioactivity  in  the  vitreous  fluid
exceeded 48 h.
To  confirm  the  presence  of  intact  bevasiranib  in  the
different  ocular  structures,  we  employed  an  LNA-based
bioanalytical method that is specific for the intact siRNA (i.e.,
for  one  of  the  duplex  strands).  Since  both  strands  of
bevasiranib  are  present  in  equivalent  amounts  in  the
hybridization  duplex,  the  validated  hybridization  method
allows for the quantification of a single strand of bevasiranib
only (i.e., the antisense strand), which is directly proportional
to the concentration of the duplex bevasiranib (on a molar
basis).
Aqueous  fluid,  vitreous  fluid,  lens,  iris,  ciliary  body,
RPE, choroid, and retina were assayed for intact bevasiranib
24 h post-injection. Bevasiranib was generally detected in all
the  ocular  structures,  the  highest  concentrations  were
TABLE 3. DISPOSITION KINETICS OF THE TOTAL RADIOACTIVITY IN OCULAR TISSUES OF DUTCH-BELTED RABBITS FOLLOWING A SINGLE INTRAVITREAL
BOLUS INJECTION OF 3H-BEVASIRANIB.
tmax Cmax tlast AUC0-tlast AUC0-inf. %Extrapolation kel t1/2el
Group Sex Sample (h) (μg eq/g) (h) (μg eq·h/g) (μg eq·h/g) AUC0-inf. (h-1) (h)
1 Males Aqueous Fluid 24 20.1 168 1654 a A a a
1 Males Eye (Right) 6 205 168 11936 13402 10.9 0.01 55.7
1 Males Iris 72 50.1 168 5814 a A a a
1 Males Retina 72 370 168 47235 a A a a
1 Males Sclera (+ choroid) 24 88.7 168 8916 a A a a
1 Males Vitreous fluid 0 499 168 24725 25176 1.8 0.02 30
1 Females Aqueous Fluid 24 28.9 168 1812 a A a a
1 Females Eye (Right) 6 175 168 12737 14281 10.8 0.01 50.7
1 Females Iris 24 37.3 168 5282 a A a a
1 Females Retina 72 343 168 45527 a A a a
1 Females Sclera (+ choroid) 24 75.6 168 8280 a A a a
1 Females Vitreous fluid 0 372 168 24301 24840 2.2 0.02 30.7
2 Males Aqueous Fluid 24 125 168 12589 a A a a
2 Males Eye (Right) 6 781 168 71089 85914 17.3 0.01 69
2 Males Iris 72 189 168 25065 a A a a
2 Males Retina 168 683 168 98185 a A a a
2 Males Sclera (+ choroid) 6 341 168 34724 a A a a
2 Males Vitreous fluid 0 2154 168 139913 154893 9.7 0.01 51.7
2 Females Aqueous Fluid 24 127 168 10334 a A a a
2 Females Eye (Right) 6 818 168 67323 85177 21 0.01 77.7
2 Females Iris 24 149 168 18915 a A a a
2 Females Retina 168 628 168 82229 a A a a
2 Females Sclera (+ choroid) 6 381 168 29642 a A a a
2 Females Vitreous fluid 0 1896 168 117832 134198 12.2 0.01 55.1
aIt was not possible to estimate the kel with an acceptable degree of confidence due to an inability to characterize the terminal
phase. Consequently, all parameters derived from this, t1/2, AUC0-inf. and % extrapolation AUC0-inf. were not estimated.
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1003consistently observed in vitreous fluid. The variation observed
is suggestive of differences in bevasiranib distribution within
the eye between eyes and between animals.
To treat neovascular AMD, bevasiranib must reach the
RPE-Bruch’s  membrane-choroidal  complex.  The
radiolabeled bevasiranib studies show that it can reach the
retina and the RPE-Bruch’s membrane choroidal complex.
However,  the  measurement  of  total  radioactivity  leaves
uncertainty about how much of the material detected in tissues
reflect intact bevasiranib. Distribution of bevasiranib into the
tissues would be expected to lead to its metabolism by tissue
nucleases,  however  this  would  not  be  expected  to  occur
immediately or completely. Indeed, LNA analysis confirmed
the presence of intact bevasiranib in ocular tissues 24 h after
intravitreal injection, suggesting bevasiranib is not only taken
up by the tissues, but that some remains intact for an extended
period of time. The levels of bevasiranib measured in the RPE,
a tissue of interest in neovascular-AMD, ranged from 423 ngs
to 2696 ngs per sample at 24 h post-injection. Even if a fraction
of the tissue-associated bevasiranib enters the cell, it is likely
to be effective in suppressing VEGF production. These and
previously published data from our laboratory collectively
provide strong evidence that after an intravitreal or subretinal
injection bevasiranib does distribute to the retina and RPE-
Bruchs membrane- choroid complex and therefore should
effect  the  RNA  interference  mechanism  resulting  in  gene
silencing to halt the production of VEGF-A in those tissues.
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